Organized by:

Welcome words:

Javier Urzay: Deputy Director General, FARMAINDUSTRIA (Spain). "Key Note: Pharma-Biotech program, deployment and results to date"”
Amelia Martín Uranga: Responsible of the Spanish Technological Platform for Innovative Medicines, FARMAINDUSTRIA (Spain). "Innovative medicines platform"

 

Case discussions and conclusions:

María Aguirre: Health Research and Innovation Directorate, BASQUE GOVERNMENT (Spain). "The role of Public Administration in fostering the transfer of research results, from lab to the society: Health research and innovation strategy for 2020"
Andrés G. Fernández: Director, Ferrer Advanced Biotherapeutics, FERRER (Spain)“Advantages of Pharma-Biotech program for Spanish pharmaceutical industry”
Javier García Cogorro: Board Member, BIONCOTECH (Spain). “Advantages of Pharma-Biotech program for biotechnology start-ups”
Anabel Sanz: Director of Technology Transfer, CNIO (Spain) “Advantages of Pharma-Biotech program for Health Research Centers and full researchers in biotechnology”
Antonio Gómez: Scientific Liason for Spain, JANSSEN CILAG (Spain). “Advantages of Pharma-Biotech program for multinational pharmaceutical companies operating in Spain”